| Literature DB >> 26611830 |
Everardo González-González1, Mario Moisés Alvarez1,2,3,4, Alan Roberto Márquez-Ipiña1, Grissel Trujillo-de Santiago1,2,3,4, Luis Mario Rodríguez-Martínez1, Nasim Annabi2,3,5, Ali Khademhosseini2,3,4,6,7,8.
Abstract
The 2014 Ebola outbreak, the largest recorded, took us largely unprepared, with no available vaccine or specific treatment. In this context, the World Health Organization declared that the humanitarian use of experimental therapies against Ebola Virus (EBOV) is ethical. In particular, an experimental treatment consisting of a cocktail of three monoclonal antibodies (mAbs) produced in tobacco plants and specifically directed to the EBOV glycoprotein (GP) was tested in humans, apparently with good results. Several mAbs with high affinity to the GP have been described. This review discusses our current knowledge on this topic. Particular emphasis is devoted to those mAbs that have been assayed in animal models or humans as possible therapies against Ebola. Engineering aspects and challenges for the production of anti-Ebola mAbs are also briefly discussed; current platforms for the design and production of full-length mAbs are cumbersome and costly.Entities:
Keywords: Ebola; GP; epidemic; mAbs; monoclonal antibodies; therapeutic
Mesh：
Substances：
Year: 2015 PMID： 26611830 PMCID： PMC5568563 DOI： 10.3109/07388551.2015.1114465
Source DB: PubMed Journal: Crit Rev Biotechnol ISSN： 0738-8551 Impact factor: 8.429